Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
This study has been completed.
Study NCT00502073   Information provided by Sirion Therapeutics, Inc.
First Received: July 13, 2007   Last Updated: February 29, 2008   History of Changes

July 13, 2007
February 29, 2008
 
 
 
 
Complete list of historical versions of study NCT00502073 on ClinicalTrials.gov Archive Site
 
 
 
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
 

The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.

 
Phase III
Interventional
Randomized, Double-Blind, Placebo Control, Parallel Assignment
Dry Eye Syndromes
Drug: cyclosporine
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Inclusion Criteria:

  • Diagnosis of moderate to severe dry eye syndrome with or without Sjogren's syndrome or other autoimmune disease

Exclusion Criteria:

  • Intraocular or refractive surgery in the study eye within 3 months prior to study start
  • Unwilling to discontinue use of contact lenses during the run-in and duration of the study
  • Pregnancy or lactation
Both
18 Years and older
 
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00502073
 
ST-603-005
Sirion Therapeutics, Inc.
 
Study Chair: Roger Vogel, MD Sirion Therapeutics
Sirion Therapeutics, Inc.
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP